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The use low dose antipsychotic medication in managing behavioural 
disturbance in older persons with dementia  
By Stanley Mutsatsa  
City University London  
Northampton Square  
London  
 
Alois Alzheimer observed behavioural disturbances in dementia over a century ago with a 
description of his first patient. Behavioural disturbances are prominent characteristics of 
dementia and can be very distressing to the individual, their family and caregivers. These 
symptoms include agitation, aggression, disinhibition, and sleep disturbances. Up to 90% of 
patients with dementia suffer from such behavioural disorders(Muller-Spahn 2003). This high 
prevalence may be partly due to a complex interaction of cognitive deficits, psychological 
symptoms, and behavioural abnormalities. In particular, it is purported that neurodegenerative 
processes in various brain areas, like fronto-temporal cortex and limbic regions lead to a 
dysfunction of key neurotransmitters like acetylcholine, serotonin and noradrenalin, leading to 
a cocktail of behavioural symptoms with personality traits playing a modifying role. 
A large number of pharmacological treatment strategies have been used to manage 
behavioural disturbances in people with dementia. (Zaudig 1996). These have included 
antipsychotics, benzodiazepines, or anticonvulsants. Though these drugs may substantially 
reduce undesirable behaviour, they may cause adverse side effect that may impact on the 
patieŶt’s ability to perform activities of daily living.  
Historically, antipsychotic drugs have often been used to treat these behavioural abnormalities 
but the extant literature is sceptical about their long-term use for this indication (Declercq et al. 
2013). Ostensibly, their long term effectiveness is limited and there is concern about their 
propensity to induce adverse effects, including higher mortality with long-term use. The 
National Institute for Clinical Excellence (NICE) guideline on dementia cautions against the use 
of any antipsychotics for non-cognitive symptoms or challenging behaviour of dementia unless 
the person is severely distressed or there is an immediate risk of harm to them or others(NICE 
2015). However, other recent meta-analytic studies have challenged previous findings of the 
unfavourable safety profile of antipsychotics in people with dementia (Hulshof et al. 2015). 
Overall, current consensus favours the judicious treatment of aggression and psychosis with 
antipsychotics for no more than 12 weeks under carefully defined conditions (Zuidema et al. 
2015).  
Where the treatment with antipsychotics is indicated, a distinction ought to be made between 
antipsychotic treatment of severe behavioural symptoms (physical aggression or severe 
agitation) that are the result of an underlying psychotic disorder and using antipsychotics for 
sedating reasons in acute situations where psychosis is absent.  
The use of antipsychotics for an underlying psychotic disorder should only be for cases where 
severe continuous distress is affecting the quality of life of the patient, family or caregiver. 
Further, the disturbed behaviour shown by the patient should not be due to other somatic 
condition like pain, infection, hunger, constipation or other mental health conditions like 
anxiety/depression. Moreover, psychosocial interventions should have been tried without 
success and the benefit of using antipsychotics is expected to outweigh the adverse 
events(Banerjee Report 2009). Antipsychotic treatment might be justified in case of an extreme 
situation without psychosis if the behaviour is causing acute and tangible risks to the patient or 
other. Symptoms that may indicate an extreme situation are severe and harmful physical 
aggression, severe physical exhaustion, and severe eating/drinking disorders with a risk of 
malnourishment (weight loss) or dehydration. 
Any use of antipsychotics should include a full discussion with the person and carers about the 
possible benefits and risks of treatment. Currently, only risperidone has market authorization 
for the treating of behavioural and psychological symptoms of dementia though many 
antipsychotic drugs are prescribed off label for this purpose. The risperidone licence for the 
short-term treatŵeŶt of persisteŶt aggressioŶ iŶ Alzheiŵer’s deŵeŶtia was graŶted iŶ 2008 
after studies showed a clear benefit for behavioural problems for the short-term use of 
risperidone when aggression only was considered in people with dementia. 
Antipsychotics come in various formulations that include oral tablets, injections and oral liquid 
formulations. Of these, oral liquids are preferred in people with dementia as they hold several 
advantages over oral or parenteral formulation (Mutsatsa and Bressington 2013). Available 
evidence suggests that oral liquid antipsychotics such as risperidone has a similarly rapid onset 
of action as an intra-muscular injection and are equally efficacious (Currier and Allen 2000; 
Carlson et al. 2010). This makes the use of oral liquid antipsychotics suitable in emergency 
situations. For the managing of behavioural symptoms in dementia, a low dose strategy is 
preferred. A starting dose of 0.5 mg of risperidone twice daily is recommended. This dosage can 
be individually adjusted with 0.5 mg twice daily increments to 1 to 2 mg twice daily.  
In general, older people are more susceptible than younger people to the adverse effects of 
antipsychotics medication. Widely reported adverse effects are extrapyramidal symptoms, 
sedation, falls, accelerated cognitive decline, and increased risk of stroke and pneumonia. Many 
side-effects are dose related, so it is important to start treatment on the lowest dose possible, 
and gradually increase if necessary.  
In conclusion, the use of antipsychotics in dementia is indicated only exceptional cases and 
even so, this should be for a short duration.  
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